MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s00280-025-04806-4

Медицинская библиотека · Cancer chemotherapy and pharmacology · 2025

Exposure-response analysis of asciminib efficacy and safety in patients with chronic myelogenous leukemia in chronic phase.

Sy Sherwin K B, Yang Yiqun, Darstein Christelle, Yoon Deok Yong, Dasgupta Kohinoor, Kapoor Shruti, Wu Shengyuan, Kawakita Yasunori, Hoch Matthias, Grosch Kai

Клиническое исследование I фазыКлиническое исследование III фазыСтатьяПеревод в очереди

Аннотация

OBJECTIVE

This study aimed to evaluate the relationships between asciminib pharmacokinetics with efficacy in first line (1 L) and safety in 1 L and third line (3 L) patients with Philadelphia-positive chronic myeloid leukemia in chronic phase.

METHODS

The key primary efficacy endpoint in ASC4FIRST (1 L, phase 3), the week-48 major molecular response (MMR), versus asciminib exposure relationship were evaluated using linear regression model; the same model was applied to assess safety endpoints vs. exposure in ASC4FIRST, ASCEMBL (3 L, phase 3) and first-in-human (3 L, phase 1) trials based on abnormal laboratory data, vital signs and adverse events.

RESULTS

The probability of week-48 MMR in ASC4FIRST versus exposure (averaged daily AUC and Cmin) in 1 L was 70–80% for the second through fourth quartile AUC0−24 h and Cmin where majority of patients had relative dose intensity > 75%; the MMR rate in the first quartile exposure metrics was 45%. Of all safety endpoints in 1 L, the only statistically significant positive relationship with exposure was the worsening event for grade ≥ 3 lipase increase but event probabilities were low (5.8%-11.2%). Line of therapy was investigated as a covariate for all safety endpoints; newly diagnosed patients had a lower probability of all safety events occurring than in pretreated patients.

CONCLUSION

Treatment compliance optimizes the efficacy of asciminib in newly diagnosed patients. Safety incidences associated with asciminib were low. The 80 mg once-daily regimen provides an optimal benefit-risk profile in newly diagnosed patients. Similar efficacy is expected from the 40 mg twice-daily regimen in the same population.

Для цитирования: Sy Sherwin K B, Yang Yiqun, Darstein Christelle, Yoon Deok Yong, Dasgupta Kohinoor, Kapoor Shruti, Wu Shengyuan, Kawakita Yasunori, Hoch Matthias, Grosch Kai. Exposure-response analysis of asciminib efficacy and safety in patients with chronic myelogenous leukemia in chronic phase.. Cancer chemotherapy and pharmacology. 2025. DOI: 10.1007/s00280-025-04806-4.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.